MDPR-Val-Cit-PAB-MMAE (TFA)

MDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition[1].

Product Specifications

CAS Number

[2185872-76-6]

UNSPSC

12352005

Target

Drug-Linker Conjugates for ADC

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mdpr-val-cit-pab-mmae-tfa.html

Purity

99.51

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC([C@@H](N4C(C=CC4=O)=O)CN)=O)=O)=O)C=C3)=O)C)=O)=O)C.O=C(O)C(F)(F)F

Molecular Formula

C67H101F3N12O17

Molecular Weight

1403.58

References & Citations

[1]Moquist, et al. Preparation of drug conjugates of IgG1 antibodies with self-stabilizing linkers having improved physiochemical properties for treating cancers and autoimmune diseases. World Intellectual Property Organization, WO2018031690 A1. 2018-02-15.